News / Taiwan / cnyes
EirGenix August Revenue Jumps 125.91% YoY, Driven by CDMO Expansion
Health Technology · Biotechnology · cnyes · 2026-09-10
6589
EirGenix reported August 2026 revenue of NT$164 million, a 125.91% year-over-year surge, with cumulative year-to-date revenue growth reaching 78.03%.
What Happened
Monthly Revenue Surge: EirGenix reported revenue of NT$164 million for August 2026, marking a significant year-over-year increase of 125.91%, despite a month-over-month decline.
Cumulative Growth: The company's cumulative revenue for the first eight months of 2026 reached NT$996 million, representing a strong year-to-date growth rate of 78.03%.
Stock Performance: Trading at NT$47.55, the stock saw a minor decline of 0.62% over the past five days, showing no significant trend compared to the broader biotech market.
Business Focus: EirGenix specializes in the development of biosimilars and new drugs, alongside providing comprehensive CDMO services for biological products.